Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Charles N LandenLuciana L MolineroHabib HamidiJalid SehouliAustin MillerKathleen M MooreCagatay TaskıranMichael A BookmanKristina LindemannCharles AndersonRegina BergerTashanna MyersMario BeinerThomas ReidEls Van NieuwenhuysenAndrew GreenAikou OkamotoCarol AghajanianPremal H ThakerStephanie V BlankVictor K KhorChing-Wei ChangYvonne G LinSandro PignataPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Most ovarian tumors have low TMB despite BRCA1/2 mutations or HRD. Neither BRCA1/2 mutation nor HRD predicted enhanced benefit from atezolizumab. This is the first randomized double-blind trial in ovarian cancer demonstrating that genomic instability triggered by BRCA1/2 mutation or HRD is not associated with improved sensitivity to immune checkpoint inhibitors.